«Forbos» is a project company, developing an anti-inflammatory drug for treating inflammatory and degenerative joint diseases (arthritis, gout). The new drug (codename – IML) is a prodrug based on an indomethacin derivative. Due to its prodrug action, it has no market analogs and differs from NSAIDs, present in the market, in the minimization of dangerous adverse effects towards the gastrointestinal drug and its prolonged action. «Forbos» is a participant of Skolkovo Innovation Center. Preclinical trials are ongoing with the support of Russian Ministry of Education and Science.